N
Nicolas Marcoux
Researcher at Harvard University
Publications - 13
Citations - 598
Nicolas Marcoux is an academic researcher from Harvard University. The author has contributed to research in topics: Internal medicine & Lung cancer. The author has an hindex of 5, co-authored 10 publications receiving 358 citations.
Papers
More filters
Journal ArticleDOI
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Zofia Piotrowska,Hideko Isozaki,Jochen K. Lennerz,Justin F. Gainor,Inga T. Lennes,Viola W. Zhu,Nicolas Marcoux,Mandeep Banwait,Subba R. Digumarthy,Wenjia Su,Satoshi Yoda,Amanda K. Riley,Varuna Nangia,Jessica J. Lin,Rebecca J. Nagy,Richard B. Lanman,Dora Dias-Santagata,Mari Mino-Kenudson,A. John Iafrate,Rebecca S. Heist,Alice T. Shaw,Erica Evans,Corinne Clifford,Sai-Hong Ignatius Ou,Beni B. Wolf,Aaron N. Hata,Lecia V. Sequist +26 more
TL;DR: Proof of concept that RET fusions can mediate acquired resistance to EGFR TKIs and that combined EGFR and RET inhibition with osimertinib/BLU-667 may be a well-tolerated and effective treatment strategy for such patients are provided.
Journal ArticleDOI
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Nicolas Marcoux,Scott N. Gettinger,Grainne M. O'Kane,Kathryn C. Arbour,Joel W. Neal,Hatim Husain,Tracey L. Evans,Julie R. Brahmer,Alona Muzikansky,Philip Bonomi,Salvatore Del Prete,Anna Wurtz,Anna F. Farago,Dora Dias-Santagata,Mari Mino-Kenudson,Karen L. Reckamp,Helena A. Yu,Heather A. Wakelee,Frances A. Shepherd,Zofia Piotrowska,Lecia V. Sequist +20 more
TL;DR: There is a growing appreciation that EGFR-mutant NSCLCs can undergo SCLC transformation, and it is demonstrated that this occurs at an average of 17.8 months after diagnosis and cases are often characterized by Rb1, TP53, and PIK3CA mutations.
Journal ArticleDOI
OA 09.01 Characterizing the Genomic Landscape of EGFR C797S in Lung Cancer Using ctDNA Next-Generation Sequencing
Zofia Piotrowska,Rebecca J. Nagy,Stephen R. Fairclough,Richard B. Lanman,Nicolas Marcoux,Scott N. Gettinger,Taofeek K. Owonikoko,S.S. Ramalingam,L.V. Sequist +8 more
Journal ArticleDOI
Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer.
Meghan J. Mooradian,Zofia Piotrowska,Benjamin J. Drapkin,Dora Dias-Santagata,Nicolas Marcoux,Konstantinos Arnaoutakis,Rebecca J. Nagy,Richard B. Lanman,Anthony J. Iafrate,Anna F. Farago,Mari Mino-Kenudson,Aaron N. Hata,Lecia V. Sequist +12 more
Journal ArticleDOI
Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.
Zofia Piotrowska,Stephen V. Liu,Alona Muzikansky,Nicolas Marcoux,Mandeep Banwait,Sara Stevens,Kelly Goodwin,Tracey E Lafferty,Jennifer Ackil,Elizabeth A. Krueger,Rebecca S. Heist,Jessica J. Lin,Justin F. Gainor,Aaron N. Hata,Alice T. Shaw,Lecia V. Sequist +15 more
TL;DR: Osimertinib is a potent, CNS-penetrant 3rd-generation EGFR TKI, and combining osi with chemo to prolo...